Laura D Hover

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 3

Top Topics

Genome Wide Analysis

Endothelial Cells

Top Venues

Molecular cancer therapeutics

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, Lars D Engstrom, Jade Laguer, Andrew Calinisan, Allan Hebbert, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, John M Ketcham, Anthony Ivetac, Christopher R Smith, J David Lawson, Lisa Rahbaek, Jeffrey Clarine, Natalie Nguyen, Barbara Saechao, Cody Parker, Adam J Elliott, Darin Vanderpool, Quanyuan He, Laura D Hover, Julio Fernandez-Banet, Silvia Coma, Jonathan A Pachter, Jill Hallin, Matthew A Marx, David M Briere, James G Christensen, Peter Olson, Jacob Haling, Shilpi Khare
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading. Molecular cancer therapeutics (2024)
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, Lars D Engstrom, Jade Laguer, Andrew Calinisan, Allan Hebbert, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, John M Ketcham, Anthony Ivetac, Christopher R Smith, J David Lawson, Lisa Rahbaek, Jeffrey Clarine, Natalie Nguyen, Barbara Saechao, Cody Parker, Adam J Elliott, Darin Vanderpool, Quanyuan He, Laura D Hover, Julio Fernandez-Banet, Silvia Coma, Jonathan A Pachter, Jill Hallin, Matthew A Marx, David M Briere, James G Christensen, Peter Olson, Jacob Haling, Shilpi Khare
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading. Molecular cancer therapeutics (2024)
Lars D Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R Smith, Svitlana Kulyk, J David Lawson, Quanyuan He, Laura D Hover, Julio Fernandez-Banet, Jill Hallin, Darin Vanderpool, David M Briere, Alice Blaj, Matthew A Marx, Jordi Rodon Ahnert, Michael D Offin, Kathryn C Arbour, Melissa Lynne Johnson, David J Kwiatkowski, Pasi A Janne, Candace L Haddox, Kyriakos P Papadopoulos, Jason T Henry, Konstantinos Leventakos, James G Christensen, Ronald Shazer, Peter Olson
MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer. Cancer discovery (2023)